Drug Trial Radar · NCT02178722
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Last checked: Nov 19, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
444
Actual
Start
Jul 17, 2014
Primary completion
Nov 26, 2018
Study completion Nov 6, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jul 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
- Endometrial Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Gastric Cancer
- Lung Cancer
- Lymphoma
- Renal Cell Carcinoma (RCC)
- Ovarian Cancer
- Solid Tumors
- UC (Urothelial Cancer)
- Melanoma
- Bladder Cancer
- Triple Negative Breast Cancer (TNBC)
Interventions
MK-3475Drug
IV infusion
INCB024360Drug
Oral daily dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse EventsTime frame: Approximately 54 months
- Phase 2: Objective Response Rate (ORR)Time frame: Approximately 54 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
The Angeles Clinic and Research Institute
Los Angeles, California
US Davis Cancer Center
Sacramento, California
University Of Colorado Cancer Center
Aurora, Colorado
University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center
Farmington, Connecticut
Miami Cancer Institute at Baptist Health, Inc
Miami, Florida
Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute
Atlanta, Georgia
The University of Chicago Medicine
Chicago, Illinois
St. Francis Cancer Center
Topeka, Kansas
Greater Baltimore Cancer Center
Baltimore, Maryland
St. Agnes Hospital Cancer Institute
Baltimore, Maryland
The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division)
Bethesda, Maryland
University of Michigan Hospital and Health Systems
Ann Arbor, Michigan
Health Partners Institute
Saint Louis Park, Minnesota
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey
The Christ Hospital Hematology Oncology, Lindner Research Center
Cincinnati, Ohio
University of Pennsylvania Hospital
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania
Greenville Health System Cancer Institute
Greenville, South Carolina
West Cancer Center
Germantown, Tennessee
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee
University Of Texas Southwestern Medical Center At Dallas
Dallas, Texas
Virginia Cancer Specialists
Arlington, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.